Chemotherapy in Mesothelioma Project. ChiMP. Mick Peake, Jill Lemon, Liz Darlison, Jeremy Steele, Richard Stephens, Paul Taylor, Sally Moore

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Chemotherapy in Mesothelioma Project. ChiMP. Mick Peake, Jill Lemon, Liz Darlison, Jeremy Steele, Richard Stephens, Paul Taylor, Sally Moore"

Transcription

1 Chemotherapy in Mesothelioma Project ChiMP Mick Peake, Jill Lemon, Liz Darlison, Jeremy Steele, Richard Stephens, Paul Taylor, Sally Moore March 2011 Page 1 of 33

2 Table of contents 1. Introduction 4 Background 4 The Chemotherapy in Mesothelioma Project (ChiMP) 4 2. Methods 5 3. Recruitment 6 4. Patient characteristics 7 5. The number of patients given chemotherapy Reported toxicities Conclusions References Acknowledgements Appendix 1; National Steering Committee Appendix 2; Data set Appendix 3; Participating networks Appendix 4; Patients recruited by network 33 Page 2 of 33

3 Table of figures and tables Figure 1; Patient disposition 6 Figure 2; Patients recruited by network 6 Figure 3; Sex of patients 7 Figure 4; Age distribution 7 Figure 5; Disease laterality/site 8 Figure 6; Performance Status at entry 8 Figure 7; Cell Type 9 Figure 8; Number of patients receiving chemotherapy by network 11 Figure 9; Chemotherapy regimen 13 Figure 10; Treatment regimens by age 13 Figure 11; Treatment by performance status 14 Figure 12; Chemotherapy by age in patients with PS of 0 or 1 14 Figure 13; Chemotherapy by cell type 15 Figure 14; Number of cycles for first line chemotherapy 16 Figure 15; First line response by regimen 17 Figure 16; Reasons for stopping first-line treatment 18 Figure 17; Reasons for no immediate treatment 18 Table 1; Patients receiving chemotherapy by network 12 Table 2; Reported toxicities 19 Table 3; Pre and post treatment symptoms 20 Page 3 of 33

4 1. Introduction Background At the time the ChiMP project was started, the UK incidence of mesothelioma had been increasing rapidly since the late 1960s when national data on Mesothelioma first began to be collected 1. Also at the time we conceived the project, well over 2000 people a year were diagnosed with mesothelioma in the UK 2 and numbers were predicted to increase to a peak of around deaths per year occurring between the years Most patients diagnosed with mesothelioma die within eighteen months 4 with the range in median survival being 4-18 months, depending on the population studied. This dismal prognosis is, in many cases, accompanied by a variety of distressing physical symptoms, particularly chest pain, breathlessness and severe fatigue. To compound the misfortune of mesothelioma patients, unlike many other tumour sites, clinicians lack the benefit of mandated national guidelines. This contributes to a variation in management that is based on the experience and opinion of individual doctors. Additionally, mesothelioma is a relatively uncommon tumour with wide regional variation in incidence which means that some clinicians see very small numbers of new cases each year. On November 1st, 2004 Lilly UK announced that Alimta (Pemetrexed) would soon be available for the treatment of patients diagnosed with mesothelioma, it being the first licensed chemotherapy treatment for malignant pleural mesothelioma, in combination with Cisplatin. A standard treatment for those considered suitable looked imminent although approval for use within the NHS was necessary via the National Institute of Clinical Excellence (NICE). The appraisal process took over three years to complete and eventually in January 2008 NICE granted approval. It became apparent, through the lengthy approval process, that whilst individual clinicians could discuss the mesothelioma chemotherapy practice in their own geographical area, there was little or no understanding of the collective practice across England and there appeared to be a variation in what was being offered; this lack of understanding led Mesothelioma UK to secure funding to develop a time limited national chemotherapy audit project. The Chemotherapy in Mesothelioma Project (ChiMP) ChiMP was a one year national audit project, launched on 1st February 2008, with the aim of clarifying what, where and how much chemotherapy treatment was being prescribed to mesothelioma patients in England. Once completed, it was hoped that the audit would help the funders of health care assess the likely cost impact of chemotherapy treatment in Mesothelioma, by providing evidence of: the characteristics of the patient group being treated; their fitness for treatment; the levels of toxicity they experience. Additionally, it should demonstrate where such patients are being treated and give an insight into the frequency of suitable patients not being treated and perhaps some insight into why this occurs. Page 4 of 33

5 2. Methods This project comprised a time-limited national audit of the use of chemotherapy in mesothelioma. The recruitment period was 1 st February 2008 to 31 st January Firstly, a National Steering Committee (Appendix 1) was established to oversee the development and analysis of the project. A data set was agreed. A project data manager was appointed. In order to maximise participation, a user-friendly data collection form (Appendix 2) was designed and access to ChiMP for participants was arranged via the project data manager or the Mesothelioma UK website. Additionally, a ChiMP information leaflet was designed and created. Since this was entirely an audit of current clinical practice with no use of identifiable patient data, it was agreed that ethical committee approval would not be required. All lung multidisciplinary teams (MDTs), oncology centres and Lung Cancer Nurse Specialists in the UK Cancer Networks were contacted and invited to participate. (Please note: There have been area changes within the Cancer Networks since this data was collected). The project was then introduced to the British Thoracic Oncology Group (BTOG) in January 2008 and enrolment began. A quarterly Newsletter was circulated. Audit collation support (including site visits) was offered. Data collection was anonymised. We asked teams to register all sequential patients referred from a lung MDT to an oncologist for a consideration of chemotherapy. There were no limitations on age or performance status (PS). Patients with incomplete data have not been included in the main analyses, with the exception of those where only details on disease site or laterality were missing. Page 5 of 33

6 3. Recruitment Eighty-six sites from 35 networks (Appendix 3) registered for the audit. Of these, 31 networks recruited 736 patients (Figure 1). Figure 1; Patient disposition This document reports on the 681 patients with complete data from 31 regional health networks (Figure 2). Figure 2; Patients recruited by network A further 55 patients did not have complete data and results have not been presented in this report. Of these 55 patients, no data were submitted for 30 patients; 25 patients were excluded due to incomplete data. Page 6 of 33

7 4. Patient characteristics Patient characteristics were typical of patients presenting with mesothelioma. The majority (83%) of patients were male (Figure 3). Just over half (56%) the patients were aged between 61 and 75 (Figure 4).Just over half (56%) the patients presented with right sided pleural disease (Figure 4). Almost half the patients (45%) were PS 1 at entry (Figure 5). Cell type is shown in Figure 7; the majority (57%) of tumours were epithelioid. Figure 3; Sex of patients Figure 4; Age distribution Page 7 of 33

8 Figure 5; Disease laterality/site Figure 6; Performance Status at entry Page 8 of 33

9 Figure 7; Cell Type Page 9 of 33

10 5. The number of patients given chemotherapy Of the 681 patients with complete data, 364 (53%) were given chemotherapy. Of the 55 patients without complete data, whose results were therefore excluded from the analyses, 18 (33%) received chemotherapy, 6 (11%) received no chemotherapy, and for 31 patients no data were recorded. The number of patients given chemotherapy by network is shown in Figure 8 and Table 1. Network numbers and abbreviations are given in Appendix 2. Page 10 of 33

11 Figure 8; Number of patients receiving chemotherapy by network Page 11 of 33

12 Table 1; Patients receiving chemotherapy by network Network Code Network Patients With Data N Patients receiving Chemotherapy n (%) 35 G Midlands 4 4 (100) 25 SW London (97) 11 Pan B ham (95) 24 SE London (94) 30 Th Valley (89) 12 A W Mid 8 7 (88) 2 Grt Man + Cheshire (81) SWW Wales SW (74) 29 3 Counties 13 9 (69) 21 West London 3 2 (67) SCH Sc Highlands 6 4 (67) 23 NE London (61) 14 Derby/Burton (58) 8 N Trent (54) 32 S/WS/Hants (50) SCG ScGrampion 2 1 (50) 34 Kent/Medway (48) 15 Leics/N hants (47) 1 Lancs/STH Cumbria (46) 26 Devon/SW 16 7 (44) 36 N England 20 8 (40) 27 Dorset (39) SEW Wales SE 11 4 (36) 6 Yorks (33) 22 N London 3 1 (33) 31 CS Coast (29) 37 Anglia (26) 3 Mside + Cheshire 24 0 (0) 13 Mid Trent 1 0 (0) 38 S Essex 1 0 (0) Page 12 of 33

13 There was a large regional variation in the percentage of patients given chemotherapy, with a range of zero to 100% among the networks. Excluding those who recruited less than 10 patients, the highest chemotherapy rates were in South West London, Pan- Birmingham, and South East London, all of which treated more than 90% of registered patients. The lowest rates were in Merseyside and Cheshire, Central South Coast and Anglia, all of which treated less than a third of registered patients (none in Merseyside and Cheshire). Of those 364 patients with data who received chemotherapy, the majority (60%) were given a combination of Pemetrexed and Cisplatin; 28% were treated with Pemetrexed and Carboplatin and 2% with Pemetrexed alone. A further 9% received other chemotherapy (Figure 9). Figure 9; Chemotherapy regimen Figure 10; Treatment regimens by age As one would expect, a higher percentage of patients in the younger age groups received chemotherapy (Figure 10). Chemotherapy was given to 83% of patients aged less than 50 years of age, 25% of patients aged and to 14% of patients aged 81 years or more. The specific regimens chosen were similar for each age group except for the use of Carboplatin which was more often used in older patients. Page 13 of 33

14 Figure 11; Treatment by performance status Figure 12; Chemotherapy by age in patients with PS of 0 or 1 Patients with better PS were given chemotherapy more frequently than patients with poorer PS (Figure 11) with all but 3 patients treated having a PS of 0-2, and the very large majority (92%) being PS 0 or 1. The range of regimens chosen was similar for each PS group. Chemotherapy by age in patients with PS of 0 or 1 is shown in Figure 12. Page 14 of 33

15 The specific chemotherapy regimen chosen was also similar for each cell type (Figure 13), proportions of patients receiving Pemetrexed/Cisplatin or Pemetrexed/Carboplatin not being dependent on tumour cell type. Figure 13; Chemotherapy by cell type Of the 364 patients with complete data who received treatment, 326 received first line treatment. The number of cycles given in this first line treatment is shown in Figure 14. Six cycles were given to just under 30% of patients receiving either Pemetrexed/Cisplatin or Pemetrexed/Carboplatin. Page 15 of 33

16 Figure 14; Number of cycles for first line chemotherapy PEM: Pemetrexed; CISP: Cisplatin; CARB Carboplatin; GEM Gemcitabine; IPM: Irinotecan, Mitomycin and Cisplatin; MVP: Mitomycin C, Vinblastine and Cisplatin. Page 16 of 33

17 Response to first line therapy is shown in Figure 15. Five (2%) patients showed a complete response to Pemetrexed/Cisplatin. Partial responses were seen in 28% of patients treated with Pemetrexed/Cisplatin, 21% of patients treated with Pemetrexed/Carboplatin and 31% of patients treated with other regimens. Reasons for stopping first-line treatment are shown in Figure 16. Just under half the patients given Pemetrexed/Cisplatin or Pemetrexed/Carboplatin stopped treatment having completed their planned course. The percentage of patients stopping due to toxicity was greatest in patients treated with chemotherapy classed as other. Figure 15; First line response by regimen Page 17 of 33

18 Figure 16; Reasons for stopping first-line treatment The most common reason for giving no immediate treatment (44%) was that the patient was judged not fit to receive it (Figure 17). Just over one quarter of the patients declined treatment. Figure 17; Reasons for no immediate treatment Page 18 of 33

19 6. Reported toxicities Nine regional networks (network Numbers: 1, 6, 8, 25, 26, 27, 29, 32, SWW) reported post-treatment toxicities. These nine networks treated 158 patients and post-treatment toxicities reported on these patients are shown in Table 2. Table 2; Reported toxicities Toxicities Pem/Cis Pem/Carb Vinorelbine Other Neutropenia Anaemia Vomiting Nausea Constipation Neuropathy (bortezimib) Renal Respondents were asked to record the occurrence of pain, cough, dyspnoea, sweating, fatigue and anorexia both pre- and post-treatment. Results are shown in Table 3. Page 19 of 33

20 Table 3; Pre and post treatment symptoms Pain Pre-treatment grade Cough n No change Worsened Improved Unknown N/A N/A 0 0 Pre-treatment grade Dyspnoea n No change Worsened Improved Unknown N/A Pre-treatment grade Sweating n No change Worsened Improved Unknown N/A Pre-treatment grade Fatigue n No change Worsened Improved Unknown N/A Pre-treatment grade Anorexia n No change Worsened Improved Unknown N/A N/A 2 Pre-treatment n No change Worsened Improved Unknown grade N/A Page 20 of 33

21 7. Conclusions As far as we are aware, this is the largest survey of chemotherapy usage in mesothelioma in routine clinical practice. The characteristics of the study population were typical of patients presenting with mesothelioma. The majority (83%) of patients were male; just over half (56%) the patients were aged between 61 and 75;.just over half (56%) the patients presented with right sided pleural disease. Almost half the patients (45%) were PS 1 at entry; the majority (57%) of tumours were epithelioid. It has to be remembered that these patients had been selected by the Multi-Disciplinary Teams as fit enough for at least consideration of active treatment by an oncologist. Regarding fitness for treatment, 493 (72%) were PS 0 or 1. Surprisingly, 170 (34%) of these PS0-1 patients received no treatment after having seen the oncologist. Of those patients treated, the majority (60%) received Pemetrexed/Cisplatin and a significant minority (28%) received Pemetrexed/Carboplatin. Reported toxicities were very low. It is likely that this was due to significant underreporting. Occurrence rates for some symptoms were specifically sought: pain, cough, dyspnoea, sweating, fatigue and anorexia. No statistical analysis has been performed on these data. However, it is clear that symptom improvement was achieved for many patients. Page 21 of 33

22 8. References 1. McElvenny DM, Darnton AJ, Price MJ, Hodgson JT (2005), Mesothelioma mortality in Great Britain from 1968 to Occup Med (Lond) Mar;55(2): Cancer Research UK 2005 Website 3. Peto J, Hodgson J, McElvenny D Darnton A and Price M. (2005), The expected burden of mesothelioma mortality in Great retain from 2002 to British Journal of Cancer (2005) 92, Clayson H (2003), Suffering in mesothelioma: concepts and contexts. European Journal of Palliative Care 2003 ;11:5, pg PD Taylor, R Goldstein, H Anderson, C Berrisford, D Smith, P Taylor, B Townley, N Thatcher (2007), Pemetrexed based chemotherapy for malignant mesothelioma; a retrospective analysis of 100 consecutively treated patient. BTOG 2007 Poster Presentation. 9. Acknowledgements The authors would like to thank the Cancer Centres and their representatives who participated and members of the Mesothelioma Nurse Action Team for supporting this project. Mesothelioma UK also acknowledges and thanks Eli Lilly and Company Limited for providing an unrestricted educational grant in June 2007 to allow Mesothelioma UK to develop and conduct this project. Page 22 of 33

23 10. Appendix 1; National Steering Committee Dr Michael D Peake (Chair) Consultant and Senior Lecturer in Respiratory Medicine Clinical Lead, National Cancer Intelligence Network National Clinical Lead, NHS Cancer Improvement The University Hospitals of Leicester NHS Trust, Leicester Liz Darlison Macmillan Consultant Nurse, Mesothelioma UK, The University Hospitals of Leicester NHS Trust, Leicester Sally Moore Cancer Nurse Specialist, Guys & St Thomas's, London Dr Jeremy Steele MD MRCP Consultant in Medical Oncology at St Bartholomew s Hospital, the Royal London Hospital and the London Chest Hospital, London Richard J Stephens Senior Research Scientist, Cancer Division, Medical Research Council, London Dr Paul Taylor Consultant Medical Oncologist at Wythenshaw Hospital, Manchester Jill Lemon ChiMP Project Manager, Mesothelioma UK, The University Hospitals of Leicester NHS Trust, Leicester Page 23 of 33

24 11. Appendix 2; Data set Page 24 of 33

25 Page 25 of 33

26 Page 26 of 33

27 12. Appendix 3; Participating networks Registration Number for hospital site No1 Hospital Name Leicester Royal Infirmary Network Number Network Number and name 15 Leicester/Northants/Kettering (Leics/N hants) No2 Derby Royal Infirmary 14 Derby/Burton (East Midlands Zone) No3 Queens Hospital Burton 14 Derby/Burton ( East Midlands Zone) No4 Clatterbridge Hospital Wirrell 3 3 Merseyside/Cheshire (Mers/Ch) No5 Northampton General Hospital 15 Leicester/Northants/Kettering (Leics/N hants) No6 Kettering General Hospital 15 Leicester/Northants/Kettering (Leics/N hants) No7 Guy s and St Thomas s 24 South East London (SE London) Hospital London No8 Torbay Hospital South Devon 26 Peninsula No9A Dorset Cancer Centre 27 Dorset Poole 9B Dorset County Hospital 27 Dorset 9C- Was registered to No 67 No10 No11 Royal Bournemouth Hospital Kingsmill Hospital Nottingham Sherwood Forest NHS Trust Queen Alexandra Hospital Portsmouth 27 Dorset 13 Mid Trent 31 Central South Coast (CS Coast) No12 Castle Hill Hospital Hull 7 Humber & Yorkshire Coast No 13 No14 No15 Medway Maritime Hospital St Mary s Hospital London Luton & Dunstable McMillan Centre 34 Kent & Medway (Kent/Medway) 21 West London 21 West London Page 27 of 33

28 Registration Number for hospital site No16 No17 No18 No19 No20 No21 No22 No23 No24 No25 Hospital Name East Surrey Hospital (Affiliated to St Lukes Cancer Centre for treatment) Russells Hall Hospital Dudley West/Mid Walsgrave Hospital Coventry Royal Berkshire Hospital Reading Selly Oak Hospital Birmingham Weston General Hospital Somerset Papworth Hospital Cambridge Salisbury District Hospital Wiltshire St Peters Hospital Guildford Surrey St Luke s Cancer Centre Royal Surrey Network Number Network Number and name 32 Surrey, West Sussex & Hampshire (S/WS/Hants) 11 Pan Birmingham (Pan B ham) 12 Arden (A W Mid) 30 Thames Valley 11 Pan Birmingham (Pan B ham) 27 Dorset 37 Anglia 31 Central South Coast (CS Coast) 32 Surrey, West Sussex & Hampshire (S/WS/Hants) 32 Surrey, West Sussex & Hampshire (S/WS/Hants) No26 No27 No28 No29 No30 Frimley Park Hospital Camberley Surrey (Affiliated to St Lukes& Royal Surrey) Llandough Hospital Cardiff Royal Marsden Hospital Surrey Royal Marsden Fultham Road North Devon District Hospital St Richards Hospital Chichester 32 Surrey, West Sussex & Hampshire (S/WS/Hants) CVW Cardiff & Vale NHS Trust Wales 25 South West London (SW London) 26 Peninsula 32 Surrey, West Sussex & Hampshire (S/WS/Hants) No31 No32 No33 Twinned with Newcross Hospital 50 Radcliffe Hospital Oxford Lung Ca MDT (Churchill) Princess Royal Hospital Haywards Heath Sussex. Staffordshire General Hospital (Dr Brammer serves Newcross) 30 Thames Valley (Th Valley) 33 Sussex 35 Greater Midlands (G Midlands) Page 28 of 33

29 Registration Number for hospital site Hospital Name Network Number Network Number and name No34A Christie Hospital 2 Greater Manchester & Cheshire (G Man/Cheshire) No34B Wythenshaw Hospital 2 Greater Manchester & Cheshire (G Man/Cheshire) No34C Leighton Hospital 2 Greater Manchester & Cheshire (G Man/Cheshire) No35 No36 Twinned with 78 Northern General Sheffield No37 No38 North Hampshire Hospital Basingstoke Western Park Hospital Sheffield South end Hospital London South Mead Hospital North Bristol 32 Surrey, West Sussex & Hampshire (S/WS/Hants) 8 North Trent (N Trent) 38 South Essex (S Essex) 28 Avon & Somerset & Wiltshire (Av/Som/Wilts) No39 No40 No41 No42 No43 Royal Sussex County Hospital Royal Free Hospital Hampstead Royal Hampshire County Hospital Southampton General Hospital Aintree Chest Centre Liverpool (Treated at Clatterbridge) No44 Somerset Cancer Centre Musgrove Park Hospital No45 Walsgrave Hospital - The Arden cancer Centre Coventry (patients registered to No 18) No46 No47 No48 No49 James Paget Hospital Norfolk/Suffolk Peterborough District Hospital Harrogate District Hospital Yorkshire Good Hope Hospital Birmingham 33 Sussex 22 North London (N London) 32 Surrey, West Sussex & Hampshire (S/WS/Hants) 31 Central South Coast (CS Coast) 3 Merseyside & Cheshire (Mers/Ch) 27 Dorset 12 Arden (A W Mid) 16 Norfolk & Waveney 37 West Anglia 6 Yorkshire (Yorks) 11 Pan Birmingham (Pan B ham) Page 29 of 33

30 Registration Number for hospital site No50 Twinned with 33 Staffordshire General No51 Hospital Name New Cross Hospital Wolverhampton (Staffordshire) Newcastle upon Tyne Hospitals (Royal Victoria, The Freeman Hospital, Newcastle General) Network Number Network Number and name 35 Greater Midlands (G Midlands) 36 North of England No52 York Hospital 6 Yorkshire (Yorks) No53 No54 No55 No56 CNS No57 No58 Mount Vernon Cancer Centre (Watford General Hospital) Huddersfield Royal Infirmary Oncology Dept Furness General Hospital Morecombe Bay East Kent Hospitals Trust William Harvey Hospital, Willesborough Bronglais General Hospital Aberystwyth Pendle Community Hospital Lancashire East Lancashire Hospital Trust 20 Mount Vernon West Herts Trust 6 Yorkshire (Yorks) 1 Lancashire & Cumbria 34 Kent & Medway (Kent/Medway) SWW South West Wales 1 Lancashire & Cumbria (Lancs/Cumbria) No59 Royal Gwent Hospital SEW Gwent Health Care Wales No60 GlanCwyd North Wales CDW Conwy & Denbighshire Wales Cancer Treatment Centre Bodewyddan Denbighshire No61 Aberdeen Royal Infirmary SCG Scotland Grampian No62 No63 Alaw Oncology Unit, Ysbyty, Bwynedd University Hospital of North Durham NWW Bangor Wales 36 North of England Page 30 of 33

31 Registration Number for hospital site Hospital Name Network Number No64 Basildon Hospital 19 South Essex Network Number and name No65 No66 No67 9C Twinned with No 9 Dorset Ca Centre Nevill Hall Abergavenney SEW Gwent Health Care Wales Wales Singleton Hospital Swansea SWW South West Wales South Wales (To include Morriston Hospital and Neath and Port Talbot) Royal Bournemouth Hospital 27 Dorset No68 Bradford Royal Infirmary 6 Yorkshire (Yorks) No69 No70 No71 No72 St Barts and The London Hospital University Hospitals Nottingham (City/Queens) The Churchill Hospital Oxford Ninewells Hospital Stefani Unit Dundee 23 North East London (NE London) 13 Mid Trent 30 Thames Valley (Th Valley) SCT Scotland Tayside (Tayside) No73 The Lancaster Royal Infirmary and West Moreland Hospital Kendall 1 Lancashire & Cumbria (Lancs/S Cumbria) No74 Sunderland Royal Hospital 36 North of England (N England) No75 Darrent Valley Hospital Kent 34 Kent & Medway (Kent/Medway) No76 No77 Clayton Hospital Northgate Wakefield Raigmore Hospital Inverness Scotland 6 Yorkshire (Yorks) SCH Scotland Highlands (Sc Highlands) No78 Twinned with No 36 Western Park Hospital Sheffield Northern General Hospital Sheffield 8 North Trent (N Trent) Page 31 of 33

32 Registration Number for hospital site No 79 Hospital Name Lancashire Trust Preston Hospital and Chorley Hospital Network Number Network Number and name 1 Lancashire & Cumbria (Lancs/S Cumbria) No 80 Hereford Hospital 29 3 Counties No 81 No 82 No 83 No 84 No 85. No 86 Kent & Canterbury Hospital Canterbury QEQM(Queen Elizabeth Queen Mother) Margate Kent North Middlesex University Hospital Oncology Day Unit West Wales General Hospital Carmarthen West Wales St James Hospital Oncology Unit Bexley Wing. Airedale Hospital Keighley WestYorkshire 34 Kent & Medway (Kent/Medway) 34 Kent & Medway (Kent/Medway) 22 North London (N London) WW 6 Yorkshire (Yorks) 6 Yorkshire (Yorks) Page 32 of 33

33 12. Appendix 4; Patients recruited by network Page 33 of 33

Quality care. Everywhere? An audit of prostate cancer services in the UK

Quality care. Everywhere? An audit of prostate cancer services in the UK Quality care. Everywhere? An audit of prostate cancer services in the UK Foreword Why should a man who lives in Essex receive worse care and support for prostate cancer than a man who comes from Manchester?

More information

NHS ENGLAND BOARD PAPER

NHS ENGLAND BOARD PAPER NHS ENGLAND BOARD PAPER Paper: PB.15.12.2016/04 Title: Taking the cancer strategy forward: programme update Lead Director: Professor Sir Bruce Keogh, National Medical Director Cally Palmer, National Cancer

More information

National Peer Review Report: Brain and CNS Cancer Services Report 2012/2013

National Peer Review Report: Brain and CNS Cancer Services Report 2012/2013 National Peer Review Programme National Peer Review Report: Brain and CNS Cancer Services Report 2012/2013 www.nationalpeerreview.nhs.uk Brain and CNS Cancer Network (Non-Surgical) MDTs) Overall Performance

More information

The optimum time to assess complete clinical response (CR)

The optimum time to assess complete clinical response (CR) The optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin C (MMC) or Cisplatin (CisP) with or without Maintenance CisP/5FU in squamous cell carcinoma of

More information

ANNUAL REPORT ON PANCREAS AND ISLET TRANSPLANTATION

ANNUAL REPORT ON PANCREAS AND ISLET TRANSPLANTATION ANNUAL REPORT ON PANCREAS AND ISLET TRANSPLANTATION REPORT FOR 2014/2015 (1 APRIL 2005 31 MARCH 2015) PUBLISHED SEPTEMBER 2015 PRODUCED IN COLLABORATION WITH NHS ENGLAND - 1 - Contents 1 Executive Summary...

More information

National Cancer Peer Review Urology Cancer Services Report 2012/2013

National Cancer Peer Review Urology Cancer Services Report 2012/2013 National Peer Review Programme National Cancer Peer Review Urology Cancer Services Report 2012/2013 www.nationalpeerreview.nhs.uk UROLOGY Urology Local Teams Overall Performance Of the 88 reviewed against

More information

Children and young people with cancer (quality standard) Stakeholder Abbott Molecular Action for Sick Children Acupuncture Association of Chartered

Children and young people with cancer (quality standard) Stakeholder Abbott Molecular Action for Sick Children Acupuncture Association of Chartered Children and young people with cancer (quality standard) Stakeholder Abbott Molecular Action for Sick Children Acupuncture Association of Chartered Physiotherapists Alder Hey Children's NHS Foundation

More information

A primary care response to domestic abuse from research to mainstream: the IRIS story. Gene Feder. Domestic abuse summit 2018 London 4 th May 2018

A primary care response to domestic abuse from research to mainstream: the IRIS story. Gene Feder. Domestic abuse summit 2018 London 4 th May 2018 A primary care response to domestic abuse from research to mainstream: the IRIS story Gene Feder Domestic abuse summit 2018 London 4 th May 2018 Constance 43 year old care worker who had been my patient

More information

Modernising radiotherapy services in England Public consultation guide

Modernising radiotherapy services in England Public consultation guide Modernising radiotherapy services in England Public consultation guide NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing Trans. & Corp.

More information

National Peer Review Report: Wales Paediatric Diabetes 2014

National Peer Review Report: Wales Paediatric Diabetes 2014 National Peer Review Report: Wales Paediatric Diabetes 2014 An overview of the findings from the 2014 National Peer Review of Paediatric Diabetes Services in Wales 1 Contents 1.0 Introduction... 3 1.1

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Smoking Cessation in Secondary Care: list of registered stakeholders

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Smoking Cessation in Secondary Care: list of registered stakeholders NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Smoking Cessation in Secondary Care: list of registered stakeholders List of Registered Stakeholders as of 4 th June 2013 20s Plenty for Us Abbey Community

More information

What Happens When Therapy Fails? Therapist Information Sheet

What Happens When Therapy Fails? Therapist Information Sheet What Happens When Therapy Fails? Therapist Information Sheet Research suggests that most people undertaking therapy have a helpful experience, but sometimes therapy goes wrong. (We use the term therapy

More information

Autism - Adults Stakeholders

Autism - Adults Stakeholders Autism - Adults Stakeholders Abertawe Bro Morgannwg University Health Board Action for Aspergers Adult Autism Additional Support Team Alder Hey Children's NHS Foundation Trust Ambitious about autism Asperger

More information

TRANSPLANT ACTIVITY IN THE UK

TRANSPLANT ACTIVITY IN THE UK Activity Report 2010/11 TRANSPLANT ACTIVITY IN THE UK www.nhsbt.nhs.uk PREFACE This report has been produced by Statistics and Clinical Audit, NHS Blood and Transplant. All figures quoted in this report

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Body mass index and waist circumference thresholds for intervening to prevent ill health among black, Asian and other minority ethnic groups List of

More information

This report has been produced by Statistics and Clinical Audit, NHS Blood and Transplant.

This report has been produced by Statistics and Clinical Audit, NHS Blood and Transplant. Preface This report has been produced by Statistics and Clinical Audit, NHS Blood and Transplant. All figures quoted in this report are as reported to NHS Blood and Transplant by 17 June 2012 for the UK

More information

Course / Meeting Course/Meeting Date Venue Re-accreditation Credits

Course / Meeting Course/Meeting Date Venue Re-accreditation Credits ACTA Autumn meeting 13-Nov-14 The Draycott Conference Centre, London Total 4 (2 per day) 3rd Annual Intensive Exam Orientated Congenital Echocardiography Course 11 & 12 November 2015 Royal Marsden Education

More information

VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS CANCER, CHEMOTHERAPY AND CLOTS

VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS CANCER, CHEMOTHERAPY AND CLOTS VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS CANCER, CHEMOTHERAPY AND CLOTS OCTOBER 2016 CONTENTS Chair s Foreword: Andrew Gwynne MP 3 Summary of Findings 4 Aims and Objectives 5 Results 7 Discussion

More information

This report has been produced by Statistics and Clinical Audit, NHS Blood and Transplant.

This report has been produced by Statistics and Clinical Audit, NHS Blood and Transplant. Preface This report has been produced by Statistics and Clinical Audit, NHS Blood and Transplant. All figures quoted in this report are as reported to NHS Blood and Transplant by 20 May 2013 for the UK

More information

VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS CANCER, CHEMOTHERAPY AND CLOTS

VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS CANCER, CHEMOTHERAPY AND CLOTS VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS CANCER, CHEMOTHERAPY AND CLOTS OCTOBER 2016 CONTENTS Chair s Foreword: Andrew Gwynne MP 3 Summary of Findings 4 Aims and Objectives 5 Results 7 Discussion

More information

Eligibility, patient pathway & treatment. Amy Campbell Clinical Trial Coordinator

Eligibility, patient pathway & treatment. Amy Campbell Clinical Trial Coordinator Eligibility, patient pathway & treatment Amy Campbell Clinical Trial Coordinator Trial design Eligible patients consenting to OPTIMA 4500 patients 100 UK sites 4 years recruitment Randomisation 2250 2250

More information

Technology appraisal guidance Published: 23 January 2008 nice.org.uk/guidance/ta135

Technology appraisal guidance Published: 23 January 2008 nice.org.uk/guidance/ta135 Pemetrexed ed for the treatment of malignant pleural mesothelioma Technology appraisal guidance Published: 23 January 2008 nice.org.uk/guidance/ta135 NICE 2017. All rights reserved. Subject to Notice of

More information

Hospital Caterers Association

Hospital Caterers Association Hospital Caterers Association www.hospitalcaterers.org Patron Application Pack 1 Contents What is the Hospital Caterers Association? 3 Branches of The Association 4 Why become a Patron 5 How to join 6

More information

Smokers and overweight patients: Soft targets for NHS savings? Smokers and overweight patients: soft targets for NHS savings?

Smokers and overweight patients: Soft targets for NHS savings? Smokers and overweight patients: soft targets for NHS savings? Smokers and overweight patients: Soft targets for NHS savings? Smokers and overweight patients: soft targets for NHS savings? 2 3 The Royal College of Surgeons of England Contents Executive summary 2 Main

More information

In this newsletter we also have a meet the team profile, tips and reminders, information on a new CTIMP study and dates for your diary.

In this newsletter we also have a meet the team profile, tips and reminders, information on a new CTIMP study and dates for your diary. Dear Colleagues, Firstly, we would like to say a big thank you to everyone for working to complete CRFs over the last two months. We managed to get 1119 completed CRFs out of 1139! Fiona has now pulled

More information

Pauline Mary Christmas PhD MSc MCSP SRP

Pauline Mary Christmas PhD MSc MCSP SRP Pauline Mary Christmas PhD MSc MCSP SRP 07854831486 pmchristmas@googlemail.com PROFILE: Consultant physiotherapist for the management of spasticity in children at Birmingham Community NHS FoundationTrust.

More information

End of Life Care Strategy

End of Life Care Strategy End of Life Care Strategy The National Council for Palliative Care Submission August 1st 2006 Contents Page No. 1. Introduction 1 2. Key matters for consideration 1 3. Definition of End of Life Care 1

More information

The number of patients waiting on the pancreas transplant list fell by 7% during the year, to 252 at 31 March 2015

The number of patients waiting on the pancreas transplant list fell by 7% during the year, to 252 at 31 March 2015 6 Pancreas Activity Pancreas Activity Key messages The number of patients waiting on the pancreas transplant list fell by 7% during the year, to 252 at 31 March 2015 The number of pancreas donors after

More information

UK Cystic Fibrosis Registry

UK Cystic Fibrosis Registry UK Cystic Fibrosis Registry Annual Data Report 2013: Summary July 2014 Contents Introduction 2 Summary of findings 3 About the Registry 3 Key facts about the UK cystic fibrosis population in 2013 4 Clinical

More information

FLUORIDATED POST CODES AREAS OF THE UK

FLUORIDATED POST CODES AREAS OF THE UK FLUORIDATED POST CODES AREAS OF THE UK Part 1: English Areas With Artificial fluoridation Health Authority area % of population with fluoridated water supply WEST MIDLANDS Burntwood, Lichfield & Tamworth

More information

Action Mesothelioma Day Here is our second bulletin for Action Mesothelioma Day (AMD) on Friday 1 July 2011.

Action Mesothelioma Day Here is our second bulletin for Action Mesothelioma Day (AMD) on Friday 1 July 2011. Action Mesothelioma Day 2011 Dear All Here is our second bulletin for Action Mesothelioma Day (AMD) on Friday 1 July 2011. Mesothelioma UK will communicate events for the day to everyone and anyone interested.

More information

Improving care for lung cancer patients:

Improving care for lung cancer patients: Improving care for lung cancer patients: a collaborative approach Improvement stories from lung cancer teams Acknowledgements The Improving Lung Cancer Outcomes Project (ILCOP) was funded through the Health

More information

The number of patients waiting on the pancreas transplant list fell by 1% during the year, to 224 at 31 March 2017

The number of patients waiting on the pancreas transplant list fell by 1% during the year, to 224 at 31 March 2017 6 Pancreas Activity Pancreas Activity Key messages The number of patients waiting on the pancreas transplant list fell by 1% during the year, to 224 at 31 March 2017 The number of pancreas donors after

More information

Cerebral palsy in children and young people quality standard stakeholder list

Cerebral palsy in children and young people quality standard stakeholder list Cerebral palsy in children and young people quality standard stakeholder list 5 Boroughs Partnership NHS Foundation Trust Action Cerebral Palsy Action on Hearing Loss Acupuncture Association of Chartered

More information

PREVIOUS EMPLOYMENT. Associate OT : CJ Occupational Therapy * Assessment and treatment for adults with neurological conditions

PREVIOUS EMPLOYMENT. Associate OT : CJ Occupational Therapy * Assessment and treatment for adults with neurological conditions CURRICULUM VITAE Katie Hanagarth Green Owl Therapy Office 3, 36 Greenhill Street Stratford-upon-Avon CV37 6LE Tel: 01789 413960 / 07966 573317 Email: katie@greenowltherapy.co.uk - Web: www.greenowltherapy.co.uk

More information

There are a number of national guidelines and performance standards which support the implementation of a straight to CT pathway.

There are a number of national guidelines and performance standards which support the implementation of a straight to CT pathway. December 2015 CONTENTS Contents... 2 1 Introduction... 3 2 Case for Change... 3 3 Evidence... 3 3.1 National and regional policy... 3 3.2 Local audit... 4 4 Supporting Work Initiatives... 5 4.1 Identification

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cook G, Williams C, Brown JM, et al, on behalf

More information

THE BRITISH THORACIC SOCIETY 17 DOUGHTY STREET LONDON WC1N 2PL TELEPHONE FAX WEBSITE

THE BRITISH THORACIC SOCIETY 17 DOUGHTY STREET LONDON WC1N 2PL TELEPHONE FAX WEBSITE THE BRITISH THORACIC SOCIETY 17 DOUGHTY STREET LONDON WC1N 2PL TELEPHONE 020 7831 8778 FAX 020 7831 8766 WEBSITE www.brit-thoracic.org.uk DESIGNED AND PRODUCED BY JTDA@ TEL 01684 575021 Email julie@jtda.co.uk

More information

Ovarian Cancer Quality Performance Indicators

Ovarian Cancer Quality Performance Indicators Ovarian Cancer Quality Performance Indicators Patients diagnosed between October 2013 and September 2016 Publication date 20 February 2018 An Official Statistics publication for Scotland This is an Official

More information

Association of British Neurologists. Acute Neurology services survey 2017

Association of British Neurologists. Acute Neurology services survey 2017 Association of British Neurologists Acute Neurology services survey 2017 1 March 2017 Prepared by: On behalf of the ABN Executive: Acknowledgement: Ralph Gregory David Nicholl Joanne Lawrence Phil Smith

More information

Diabetes and Obesity. Meeting the Challenges in Physical Activity and Exercise. Jenni Jones. BACPR President Friday 11 th May 2012, BACPR-EPG, Aston

Diabetes and Obesity. Meeting the Challenges in Physical Activity and Exercise. Jenni Jones. BACPR President Friday 11 th May 2012, BACPR-EPG, Aston Promoting Excellence in Cardiovascular Disease Prevention and Rehabilitation Diabetes and Obesity Meeting the Challenges in Physical Activity and Exercise Jenni Jones BACPR President Friday 11 th May 2012,

More information

Fracture Liaison Service Database (FLS-DB) clinical audit FLS forward: Identifying high-quality care in the NHS for secondary fracture prevention

Fracture Liaison Service Database (FLS-DB) clinical audit FLS forward: Identifying high-quality care in the NHS for secondary fracture prevention Fracture Liaison Service Database (FLS-DB) clinical audit FLS forward: Identifying high-quality care in the NHS for secondary fracture prevention April 2017 In association with: Commissioned by: FLS forward:

More information

We are delighted to introduce Alison Blake, our latest advisor, who is due to join us in June 2017

We are delighted to introduce Alison Blake, our latest advisor, who is due to join us in June 2017 LONDON ASBESTOS SUPPORT AWARENESS GROUP LTD FOR LONDON & THE SOUTH EAST LASAG LTD Freephone Helpline 0808 278 2515 www.lasag.org NEWSLETTER LASAG Advisors Marika Townsend marika.lasag@gmail.com Educated

More information

Evidence review for Surrey Prescribing Clinical Network SUMMARY

Evidence review for Surrey Prescribing Clinical Network SUMMARY East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Surrey Prescribing Clinical Network Medicine

More information

Q3 Statistical Report 2017

Q3 Statistical Report 2017 Q Statistical Report 07 Summary Overall Quarter Observations During this quarter, the Helpline saw a steady increase in number calls rising from 7 in July to 7 in September. We had an unprecedented 94

More information

Clinical Research Facilities. Guide to using the NIHR identity

Clinical Research Facilities. Guide to using the NIHR identity Clinical Research Facilities Guide to using the NIHR identity 1. Introduction (NIHR) was established in April 2006 to provide the framework through which the Department of Health can position, maintain

More information

Provisional 1 monthly topic of interest: Victorian diseases 2

Provisional 1 monthly topic of interest: Victorian diseases 2 Provisional 1 monthly topic of interest: Victorian diseases 2 This topic examines recent hospital admissions data due to a range of diseases that were widespread during the 19th and early 2th centuries.

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Public Health Programme Looked after children

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Public Health Programme Looked after children NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Public Health Programme Looked after children List of Registered Stakeholders as of 5 th August 2010 A National Voice Action for Children Action on

More information

The Blue Light project: The story. A report on progress to March 2016

The Blue Light project: The story. A report on progress to March 2016 The Blue Light project: The story so far A report on progress to March 2016 The Blue Light project is an innovative and cost effective approach to tackling one of the most challenging groups in the community:

More information

List of Registered Services. South Tyneside NHS Foundation Trust

List of Registered Services. South Tyneside NHS Foundation Trust List of Registered Services North East Adult Psychology, Working Age Adult Service Alliance Psychological Services Clinical Psychology, South Tyneside Community Treatment Team Gateshead Primary care mental

More information

Patient Support Groups

Patient Support Groups 1 Patient Support Groups As well as support available from the Asbestos Support Group (ASG) there are an increasing number of Mesothelioma specific support groups. Some are run by the ASGs and held within

More information

Lung cancer clinical outcomes publication 2016 (for the 2014 audit period)

Lung cancer clinical outcomes publication 2016 (for the 2014 audit period) Society for Cardiothoracic Surgery in Great Britain and Ireland Lung cancer clinical outcomes publication 2016 (for the 2014 audit period) December 2016 In association with: The Royal College of Physicians

More information

Technology appraisal guidance Published: 25 November 2009 nice.org.uk/guidance/ta184

Technology appraisal guidance Published: 25 November 2009 nice.org.uk/guidance/ta184 Topotecan for the treatment of relapsed small-cell lung cancer Technology appraisal guidance Published: 25 November 2009 nice.org.uk/guidance/ta184 NICE 2017. All rights reserved. Subject to Notice of

More information

Organ Donation and Transplantation. Activity Report 2015/16

Organ Donation and Transplantation. Activity Report 2015/16 Organ Donation and Transplantation Activity Report 2015/16 Preface This report has been produced by Statistics and Clinical Studies, NHS Blood and Transplant. All figures quoted in this report are as reported

More information

Dermatological content of U.K. undergraduate curricula in 2015: full report

Dermatological content of U.K. undergraduate curricula in 2015: full report Dermatological content of U.K. undergraduate curricula in 2015: full report A Yaakub 1, SN Cohen 2, M Singh 3, JMR Goulding 4 1 Norfolk and Norwich University Hospital, Norwich, U.K. 2 Royal Liverpool

More information

Scottish Pathology Network (SPAN) Progress Report Oct 2008

Scottish Pathology Network (SPAN) Progress Report Oct 2008 Scottish Pathology Network (SPAN) Progress Report Oct 2008 SPAN SPAN Pathology configuration in Scotland Operation of the network Context (diagnostics in Scotland) Common challenges Concerted responses

More information

Referral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual Report

Referral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual Report Referral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual Report 1 Referral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual

More information

Referral guide for acute oncology emergencies

Referral guide for acute oncology emergencies Referral guide for acute oncology emergencies 1 st Edition v 1.0 London Cancer March 2013 To be used in conjunction with London Cancer clinical guidelines for acute oncology emergencies; A Guide to Acute

More information

NHS Dental Statistics for England: 2009/10

NHS Dental Statistics for England: 2009/10 NHS Dental Statistics for England: 2009/10 Copyright 2010, The Health and Social Care Information Centre, Dental and Eye Care Team. All Rights Reserved. 1 The NHS Information Centre is England s central,

More information

Programme Day : Chairman s introduction : Supportive care an overview Declan Walsh

Programme Day : Chairman s introduction : Supportive care an overview Declan Walsh Inaugural Guildford Supportive Care in Cancer Course 4 th -5 th November 2015 Royal College of Physicians, London Background The Multinational Association for Supportive Care in Cancer (MASCC) has defined

More information

Behaviour change: general approaches (Oct 2017) Stakeholders

Behaviour change: general approaches (Oct 2017) Stakeholders Behaviour change: general approaches (Oct 2017) Stakeholders 20s Plenty for us Abbey Community Association Ltd Action on Hearing Loss Active Stirling Addaction ADFAM Affinity AIM - Alcohol in Moderation

More information

Services participating in round 2 of the National Audit of Psychological Therapies

Services participating in round 2 of the National Audit of Psychological Therapies s participating in round 2 of the National Audit of Psychological Therapies Below is a regional breakdown of services registered for the second round of the National Audit of Psychological Therapies. East

More information

C Orkin, 1 G Moyle, 2 M Fisher, 3 H Wang, 4 J Ewan 4 and ROCKET I Study Group. Chelsea and Westminster Hospital, London, UK;

C Orkin, 1 G Moyle, 2 M Fisher, 3 H Wang, 4 J Ewan 4 and ROCKET I Study Group. Chelsea and Westminster Hospital, London, UK; Switching from Kivexa [KVX] (ABC/3TC) + Efavirenz [EFV] to [ATR] (EFV/FTC/TDF) Reduces Cholesterol in Hypercholesterolaemic Subjects: Primary Endpoint Results of a 24- Week Randomised Study C Orkin, 1

More information

An outline of the project which Pfizer's Medical and Educational Goods and Services grant supported

An outline of the project which Pfizer's Medical and Educational Goods and Services grant supported Medical and Educational Goods and Services (MEGS) grants paid by Pfizer in 2013 to UK Organisations, Associations and Institutions that are comprised of health professionals and /or that provide healthcare

More information

Multidisciplinary Hypodontia Clinics

Multidisciplinary Hypodontia Clinics 1 Multidisciplinary Hypodontia Clinics This section is intended to support dental healthcare professionals in helping individuals with Hypodontia. The EDS has found that dental problems are a principal

More information

Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Haematology Cancer Network Site Specific Group.

Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Haematology Cancer Network Site Specific Group. Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Haematology Cancer Network Site Specific Group Annual Report 2014 Version 1.0 1 This annual report was prepared by: Sophie Otton Chair

More information

CARDIAC REHABILITATION PROGRAMME FINDER WALES A-Z BY COUNTY

CARDIAC REHABILITATION PROGRAMME FINDER WALES A-Z BY COUNTY CARDIAC REHABILITATION PROGRAMME FINDER WALES A-Z BY COUNTY Programme: Aneurin Bevan University Health Board (North Gwent Cardiac Rehab & Aftercare), Abergavenny Contact: Suzanne Indge Telephone: 01873

More information

Specialist Palliative Care Referral for Patients

Specialist Palliative Care Referral for Patients Specialist Palliative Care Referral for Patients This guideline covers referrals for patients with progressive terminal illness, whether due to cancer or other disease. For many patients in the late stages

More information

Attention deficit hyperactivity disorder (update) (Feb 2018) Stakeholders

Attention deficit hyperactivity disorder (update) (Feb 2018) Stakeholders Attention deficit hyperactivity disorder (update) (Feb 2018) Stakeholders 2gether NHS Foundation Trust 5 Boroughs Partnership NHS Foundation Trust Aberdeen Chiropractic Clinic Abertawe Bro Morgannwg University

More information

NHS Bowel Cancer Screening Programme

NHS Bowel Cancer Screening Programme NHS Bowel Cancer Screening Programme Wolverhampton Bowel Cancer Screening Centre Annual Report April 2015 to March 2016 Introduction Bowel cancer is the fourth most common cancer in the UK (2012) accounting

More information

Commissioning Living with and Beyond Cancer in Yorkshire and Humber; an Overview.

Commissioning Living with and Beyond Cancer in Yorkshire and Humber; an Overview. Commissioning Living with and Beyond Cancer in Yorkshire and Humber; an Overview. Document Title An Overview of Commissioning Living with and Beyond Cancer in Yorkshire and Humber Version number: 1 First

More information

Tuberculosis in Wales Annual Report 2013

Tuberculosis in Wales Annual Report 2013 Tuberculosis in Wales Annual Report 2013 Author: Communicable Disease Surveillance Centre Date: 16/12/13 Version: 1 Status: Final Intended Audience: Health Purpose and Summary of Document: This report

More information

22 nd INFANT HIP ULTRASOUND COURSE (GRAF COURSE) UPDATE COURSE

22 nd INFANT HIP ULTRASOUND COURSE (GRAF COURSE) UPDATE COURSE 22 nd INFANT HIP ULTRASOUND COURSE (GRAF COURSE) UPDATE COURSE Feedback - June 2016 22nd INFANT HIP ULTRASOUND COURSE (GRAF COURSE) UPDATE COURSE This Update Course, previously run in Dorchester as the

More information

Achieving World-Class Cancer Outcomes: A Strategy for England Progress Report

Achieving World-Class Cancer Outcomes: A Strategy for England Progress Report Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020 NATIONAL CANCER TRANSFORMATION PROGRAMME Publications Gateway Reference: 07318 2 A Strategy for England 2015-2020 Contents Foreword

More information

Eli Lilly and Company Ltd

Eli Lilly and Company Ltd www.lilly.co.uk Eli Lilly and Company Limited Lilly House Priestley Road Basingstoke Hampshire RG24 9NL Medical and Product Information: +44 (0) 1256 315999 28 February 2007 Mr Christopher Feinmann Technology

More information

Strategic Clinical Network for Yorkshire and the Humber

Strategic Clinical Network for Yorkshire and the Humber Strategic Clinical Network for Yorkshire and the Humber SCN-CVD-Nephrology-AKI John Stoves Park Plaza, Leeds 16 th June 2014 2 Strategic Clinical Networks SCNs operate as engines for change across complex

More information

North West ChiMatters Child and Maternal Health Intelligence Briefing

North West ChiMatters Child and Maternal Health Intelligence Briefing North West ChiMatters Child and Maternal Health Intelligence Briefing Children with long-term conditions in the North West: Emergency hospital admissions for asthma, diabetes and epilepsy 28/9 March 211

More information

The Breast Health Practice GenesisCare, Milton Keynes. Swift, reassuring, professional. breasthealthmk.co.uk

The Breast Health Practice GenesisCare, Milton Keynes. Swift, reassuring, professional. breasthealthmk.co.uk The Breast Health Practice GenesisCare, Milton Keynes Swift, reassuring, professional. breasthealthmk.co.uk Introducing The Breast Health Practice If you are concerned about a breast problem it can be

More information

Centre for Specialist Psychological Treatments of Anxiety and Related Problems

Centre for Specialist Psychological Treatments of Anxiety and Related Problems Centre for Specialist Psychological Treatments of Anxiety and Related Problems Information for people interested in accessing treatment at the Centre and those who already have a referral Welcome Welcome

More information

Relationships with Healthcare Organisations, Patient Organisations and Healthcare Professionals

Relationships with Healthcare Organisations, Patient Organisations and Healthcare Professionals Relationships with Healthcare s, Patient s and Healthcare Professionals Healthcare and Patient s CSL Behring makes available a number grants to Healthcare and Patient s. Grants are made in accordance with

More information

The adult social care workforce supporting people with learning disabilities and/or autism Data from the National Minimum Data Set for Social Care

The adult social care workforce supporting people with learning disabilities and/or autism Data from the National Minimum Data Set for Social Care The adult social care workforce supporting people with learning disabilities and/or autism Data from the National Minimum Data Set for Social Care July 2016 2 The adult social care workforce supporting

More information

Brief Audit of Platelet Use in the Yorkshire and The Humber Region

Brief Audit of Platelet Use in the Yorkshire and The Humber Region Brief Audit of Platelet Use in the Yorkshire and The Humber Region Anne Davidson, Patient Blood Management Practitioner, Yorkshire and The Humber Regional Transfusion Committee Introduction This project

More information

Technology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta402

Technology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta402 Pemetrexed ed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed ed and cisplatin Technology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta402 NICE

More information

PATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE

PATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE PATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE Procedure Reference: Document Owner: Dr V. Misra Version: Accountable Committee: V3 MSCC Network

More information

Deaths from liver disease. March Implications for end of life care in England.

Deaths from liver disease. March Implications for end of life care in England. National End of Life Care Programme Improving end of life care Deaths from liver Implications for end of life care in England March 212 www.endoflifecare-intelligence.org.uk Foreword The number of people

More information

Have you logged on and updated your details recently? Go to ukmsregister.org to answer the latest questionnaires!

Have you logged on and updated your details recently? Go to ukmsregister.org to answer the latest questionnaires! UK MS Register June 2015 Issue 7 What s inside? Page 1 2 3 5 8 9 In this edition... The UK MS Register map Results Collaborations Events Contact In this edition... Focussing on collaboration, we are continuing

More information

Hospital Norovirus Outbreak Reporting

Hospital Norovirus Outbreak Reporting Second Report of the Health Protection Agency. Hospital Norovirus Outbreak Reporting Summary findings In January 2009 the HPA in conjunction with the Infection Prevention Society launched a voluntary National

More information

Life After Prostate Cancer Diagnosis Research Study

Life After Prostate Cancer Diagnosis Research Study Life After Prostate Cancer Diagnosis Research Study If you are looking at this information sheet this means you have read the covering letter and therefore have had a diagnosis of prostate cancer. If you

More information

Friday 15 September 2017 Issue 2. Content Section headings indicate whether UK or England interest

Friday 15 September 2017 Issue 2. Content Section headings indicate whether UK or England interest Friday 15 September 2017 Issue 2 Content Section headings indicate whether UK or England interest Dates for your diary... 4 Frailty Contractual Guidance on Batch-coding.... 3 Funding General Practice in

More information

Fixing footcare in Sheffield: Improving the pathway

Fixing footcare in Sheffield: Improving the pathway FOOTCARE CASE STUDY 1: FEBRUARY 2015 Fixing footcare in Sheffield: Improving the pathway SUMMARY The Sheffield Teaching Hospitals NHS Foundation Trust diabetes team transformed local footcare services

More information

Royal College of Physicians (RCP) National Clinical Guidelines for Stroke. Final Accreditation Report. Guidance producer: Guidance product:

Royal College of Physicians (RCP) National Clinical Guidelines for Stroke. Final Accreditation Report. Guidance producer: Guidance product: Guidance producer: Royal College of Physicians (RCP) Guidance product: National Clinical Guidelines for Stroke Date: 29 June 2010 Final Accreditation Report Contents Contents... 2 Introduction... 3 Implementation...

More information

Improving Value in Chemotherapy

Improving Value in Chemotherapy Improving Value in Chemotherapy Nathan Hall March 2017 Content 1. Financial Context 2. What does Improving Value mean? 3. How can we Improve Value in Chemotherapy? 2 Our Context There is an ever increasing

More information

LCA Mental Health & Psychological Support Mapping

LCA Mental Health & Psychological Support Mapping LCA Mental Health & Psychological Support Mapping November 2013 Contents 1 Introduction... 3 2 Method... 3 3 Results... 3 3.1 Information Centres... 3 3.2 Training and Education... 5 3.3 Level Two Supervision...

More information

Palliative Care The Benefits of Early Intervention

Palliative Care The Benefits of Early Intervention The Royal Marsden Palliative Care The Benefits of Early Intervention Dr Anna-Marie Stevens, Nurse Consultant Symptom Control and Palliative Care Team, The Royal Marsden NHS Foundation Trust, London, UK

More information

Vital statistics Findings from the National Gay Men s Sex Survey 1999

Vital statistics Findings from the National Gay Men s Sex Survey 1999 Vital statistics Findings from the National Gay Men s Sex Survey 1999 Peter Weatherburn Michael Stephens David Reid Ford Hickson Laurie Henderson Dale Brown Original Research Report Acknowledgments Collaborating

More information

An Update in Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar State (HHS)

An Update in Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar State (HHS) An Update in Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar State (HHS) Dr Ketan Dhatariya MBBS MSc MD MS FRCP Consultant in Diabetes and Endocrinology Norfolk and Norwich University Hospitals

More information

MUSCULOSKELETAL CALCULATOR 42,103. 1in6 SUMMARY. Second Local Authority Bulletin Prevalence of back pain in England and Wolverhampton

MUSCULOSKELETAL CALCULATOR 42,103. 1in6 SUMMARY. Second Local Authority Bulletin Prevalence of back pain in England and Wolverhampton MUSCULOSKELETAL CALCULATOR Second Local Authority Bulletin Prevalence of back pain in England and Wolverhampton 42,103 estimated people in Wolverhampton live with back pain SUMMARY Arthritis Research UK

More information

Technology appraisal guidance Published: 23 August 2006 nice.org.uk/guidance/ta107

Technology appraisal guidance Published: 23 August 2006 nice.org.uk/guidance/ta107 Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer Technology appraisal guidance Published: 23 August 2006 nice.org.uk/guidance/ta107 NICE 2017. All rights reserved. Subject

More information

Guidance on the use of imatinib for chronic myeloid leukaemia

Guidance on the use of imatinib for chronic myeloid leukaemia Guidance on the use of imatinib for chronic myeloid Issued: October 2003 last modified: January 2012 guidance.nice.org.uk/ta70 NICE 2003 Contents 1 Guidance... 3 2 Clinical need and practice... 4 3 The

More information